An open multicenter trial of conversion from sandimmun to neoral in stable kidney-transplant patients
Results obtained in organ transplantation have considerably improved with the introduction of Cyclosporine (CsA). However, the management of the drug in the sandimmun formulation is hampered by its low, highly variable bioavailability as well as the inter- and intrasubject variability of its pharmac...
Gespeichert in:
| Veröffentlicht in: | Transplantation proceedings 1997-08, Vol.29 (5), p.2313-2314 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2314 |
|---|---|
| container_issue | 5 |
| container_start_page | 2313 |
| container_title | Transplantation proceedings |
| container_volume | 29 |
| creator | Hourmant, M. Antoine, C. Bayle, F. Bedrossian, J. Berthoux, F. Cassuto, E. Chalopin, J.M. Charpentier, B. Deteix, P. Durand, D. Hurault de Ligny, B. Kessler, M. Kreis, H. Lang, P. Lebranchu, Y. Leroux-Robert, C. Moulin, B. Mourad, G. Noël, C. Olmer, M. Potaux, L. Pouteil-Noble, C. Pruna, A. Sraër, J.D. Touchard, G. Toupance, O. Touraine, J.L. Wolf, P. Puget, S. Soulillou, J.P. |
| description | Results obtained in organ transplantation have considerably improved with the introduction of Cyclosporine (CsA). However, the management of the drug in the sandimmun formulation is hampered by its low, highly variable bioavailability as well as the inter- and intrasubject variability of its pharmacokinetic parameters. The new galenic formulation of CsA, Neoral, based on the microemulsion principle, makes CsA absorption less dependent on gastric repletion, the presence of biliary salts and pancreatic enzymes, and concomitant administration of food. Digestive absorption and, subsequently, drug bioavailability are improved. Pharmacological studies in healthy volunteers and transplanted patients
1,2 have shown that pharmacokinetic profile of CsA becomes more reproducible from patient to patient as well as in the same patient over time.
The aim of our study was to analyze the clinical outcome and the variations in the parameters of CsA monitoring after conversion from CsA-Sandimmun (SIM) to CsA-Neoral (NEO) in stable kidney recipients transplanted for more than 6 months. |
| doi_str_mv | 10.1016/S0041-1345(97)00381-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79235662</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134597003813</els_id><sourcerecordid>79235662</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-6057fe3a72d94f15d901b61299a11f7bd8348c6b44caf38eb7c0546028081e993</originalsourceid><addsrcrecordid>eNqFkE1r3DAQhkVpSTab_ISADqE0B6f6smWdSgj5gkAPbc9ClkegxpYcSQ7k31fJLnvtaRjmmZmXB6FzSq4ood33X4QI2lAu2m9KXhLCe9rwT2hDe8kb1jH-GW0OyDE6yfkvqT0T_AgdKSaJFHSD4DrguEDA8zoVbyEUSLgkbyYcHbYxvELKPgbsUpxxNmH087wGXCIOEFPFfMC5mGEC_OzHAG9NSSbkZTKh4MUUX0_mU_TFmSnD2b5u0Z-72983D83Tz_vHm-unxnJFS9ORVjrgRrJRCUfbURE6dJQpZSh1chh7LnrbDUJY43gPg7SkFR1hPekpKMW36Ovu7pLiywq56NlnC1MNA3HNWirG26662aJ2B9oUc07g9JL8bNKbpkS_69UfevW7O62k_tCred073z9YhxnGw9beZ51f7OcmWzO5qsL6fMCY7IlUXcV-7DCoMl49JJ1tFWVh9Als0WP0_wnyD0BJlzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79235662</pqid></control><display><type>article</type><title>An open multicenter trial of conversion from sandimmun to neoral in stable kidney-transplant patients</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hourmant, M. ; Antoine, C. ; Bayle, F. ; Bedrossian, J. ; Berthoux, F. ; Cassuto, E. ; Chalopin, J.M. ; Charpentier, B. ; Deteix, P. ; Durand, D. ; Hurault de Ligny, B. ; Kessler, M. ; Kreis, H. ; Lang, P. ; Lebranchu, Y. ; Leroux-Robert, C. ; Moulin, B. ; Mourad, G. ; Noël, C. ; Olmer, M. ; Potaux, L. ; Pouteil-Noble, C. ; Pruna, A. ; Sraër, J.D. ; Touchard, G. ; Toupance, O. ; Touraine, J.L. ; Wolf, P. ; Puget, S. ; Soulillou, J.P.</creator><creatorcontrib>Hourmant, M. ; Antoine, C. ; Bayle, F. ; Bedrossian, J. ; Berthoux, F. ; Cassuto, E. ; Chalopin, J.M. ; Charpentier, B. ; Deteix, P. ; Durand, D. ; Hurault de Ligny, B. ; Kessler, M. ; Kreis, H. ; Lang, P. ; Lebranchu, Y. ; Leroux-Robert, C. ; Moulin, B. ; Mourad, G. ; Noël, C. ; Olmer, M. ; Potaux, L. ; Pouteil-Noble, C. ; Pruna, A. ; Sraër, J.D. ; Touchard, G. ; Toupance, O. ; Touraine, J.L. ; Wolf, P. ; Puget, S. ; Soulillou, J.P.</creatorcontrib><description>Results obtained in organ transplantation have considerably improved with the introduction of Cyclosporine (CsA). However, the management of the drug in the sandimmun formulation is hampered by its low, highly variable bioavailability as well as the inter- and intrasubject variability of its pharmacokinetic parameters. The new galenic formulation of CsA, Neoral, based on the microemulsion principle, makes CsA absorption less dependent on gastric repletion, the presence of biliary salts and pancreatic enzymes, and concomitant administration of food. Digestive absorption and, subsequently, drug bioavailability are improved. Pharmacological studies in healthy volunteers and transplanted patients
1,2 have shown that pharmacokinetic profile of CsA becomes more reproducible from patient to patient as well as in the same patient over time.
The aim of our study was to analyze the clinical outcome and the variations in the parameters of CsA monitoring after conversion from CsA-Sandimmun (SIM) to CsA-Neoral (NEO) in stable kidney recipients transplanted for more than 6 months.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/S0041-1345(97)00381-3</identifier><identifier>PMID: 9270741</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Cyclosporine - administration & dosage ; Female ; Graft Rejection - prevention & control ; Humans ; Immunomodulators ; Immunosuppressive Agents - administration & dosage ; Kidney Transplantation ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Transplantation, Homologous ; Treatment Outcome</subject><ispartof>Transplantation proceedings, 1997-08, Vol.29 (5), p.2313-2314</ispartof><rights>1997</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-6057fe3a72d94f15d901b61299a11f7bd8348c6b44caf38eb7c0546028081e993</citedby><cites>FETCH-LOGICAL-c391t-6057fe3a72d94f15d901b61299a11f7bd8348c6b44caf38eb7c0546028081e993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0041-1345(97)00381-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,778,782,787,788,3539,23913,23914,25123,27907,27908,45978</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2780796$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9270741$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hourmant, M.</creatorcontrib><creatorcontrib>Antoine, C.</creatorcontrib><creatorcontrib>Bayle, F.</creatorcontrib><creatorcontrib>Bedrossian, J.</creatorcontrib><creatorcontrib>Berthoux, F.</creatorcontrib><creatorcontrib>Cassuto, E.</creatorcontrib><creatorcontrib>Chalopin, J.M.</creatorcontrib><creatorcontrib>Charpentier, B.</creatorcontrib><creatorcontrib>Deteix, P.</creatorcontrib><creatorcontrib>Durand, D.</creatorcontrib><creatorcontrib>Hurault de Ligny, B.</creatorcontrib><creatorcontrib>Kessler, M.</creatorcontrib><creatorcontrib>Kreis, H.</creatorcontrib><creatorcontrib>Lang, P.</creatorcontrib><creatorcontrib>Lebranchu, Y.</creatorcontrib><creatorcontrib>Leroux-Robert, C.</creatorcontrib><creatorcontrib>Moulin, B.</creatorcontrib><creatorcontrib>Mourad, G.</creatorcontrib><creatorcontrib>Noël, C.</creatorcontrib><creatorcontrib>Olmer, M.</creatorcontrib><creatorcontrib>Potaux, L.</creatorcontrib><creatorcontrib>Pouteil-Noble, C.</creatorcontrib><creatorcontrib>Pruna, A.</creatorcontrib><creatorcontrib>Sraër, J.D.</creatorcontrib><creatorcontrib>Touchard, G.</creatorcontrib><creatorcontrib>Toupance, O.</creatorcontrib><creatorcontrib>Touraine, J.L.</creatorcontrib><creatorcontrib>Wolf, P.</creatorcontrib><creatorcontrib>Puget, S.</creatorcontrib><creatorcontrib>Soulillou, J.P.</creatorcontrib><title>An open multicenter trial of conversion from sandimmun to neoral in stable kidney-transplant patients</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Results obtained in organ transplantation have considerably improved with the introduction of Cyclosporine (CsA). However, the management of the drug in the sandimmun formulation is hampered by its low, highly variable bioavailability as well as the inter- and intrasubject variability of its pharmacokinetic parameters. The new galenic formulation of CsA, Neoral, based on the microemulsion principle, makes CsA absorption less dependent on gastric repletion, the presence of biliary salts and pancreatic enzymes, and concomitant administration of food. Digestive absorption and, subsequently, drug bioavailability are improved. Pharmacological studies in healthy volunteers and transplanted patients
1,2 have shown that pharmacokinetic profile of CsA becomes more reproducible from patient to patient as well as in the same patient over time.
The aim of our study was to analyze the clinical outcome and the variations in the parameters of CsA monitoring after conversion from CsA-Sandimmun (SIM) to CsA-Neoral (NEO) in stable kidney recipients transplanted for more than 6 months.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cyclosporine - administration & dosage</subject><subject>Female</subject><subject>Graft Rejection - prevention & control</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Kidney Transplantation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1r3DAQhkVpSTab_ISADqE0B6f6smWdSgj5gkAPbc9ClkegxpYcSQ7k31fJLnvtaRjmmZmXB6FzSq4ood33X4QI2lAu2m9KXhLCe9rwT2hDe8kb1jH-GW0OyDE6yfkvqT0T_AgdKSaJFHSD4DrguEDA8zoVbyEUSLgkbyYcHbYxvELKPgbsUpxxNmH087wGXCIOEFPFfMC5mGEC_OzHAG9NSSbkZTKh4MUUX0_mU_TFmSnD2b5u0Z-72983D83Tz_vHm-unxnJFS9ORVjrgRrJRCUfbURE6dJQpZSh1chh7LnrbDUJY43gPg7SkFR1hPekpKMW36Ovu7pLiywq56NlnC1MNA3HNWirG26662aJ2B9oUc07g9JL8bNKbpkS_69UfevW7O62k_tCred073z9YhxnGw9beZ51f7OcmWzO5qsL6fMCY7IlUXcV-7DCoMl49JJ1tFWVh9Als0WP0_wnyD0BJlzw</recordid><startdate>19970801</startdate><enddate>19970801</enddate><creator>Hourmant, M.</creator><creator>Antoine, C.</creator><creator>Bayle, F.</creator><creator>Bedrossian, J.</creator><creator>Berthoux, F.</creator><creator>Cassuto, E.</creator><creator>Chalopin, J.M.</creator><creator>Charpentier, B.</creator><creator>Deteix, P.</creator><creator>Durand, D.</creator><creator>Hurault de Ligny, B.</creator><creator>Kessler, M.</creator><creator>Kreis, H.</creator><creator>Lang, P.</creator><creator>Lebranchu, Y.</creator><creator>Leroux-Robert, C.</creator><creator>Moulin, B.</creator><creator>Mourad, G.</creator><creator>Noël, C.</creator><creator>Olmer, M.</creator><creator>Potaux, L.</creator><creator>Pouteil-Noble, C.</creator><creator>Pruna, A.</creator><creator>Sraër, J.D.</creator><creator>Touchard, G.</creator><creator>Toupance, O.</creator><creator>Touraine, J.L.</creator><creator>Wolf, P.</creator><creator>Puget, S.</creator><creator>Soulillou, J.P.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970801</creationdate><title>An open multicenter trial of conversion from sandimmun to neoral in stable kidney-transplant patients</title><author>Hourmant, M. ; Antoine, C. ; Bayle, F. ; Bedrossian, J. ; Berthoux, F. ; Cassuto, E. ; Chalopin, J.M. ; Charpentier, B. ; Deteix, P. ; Durand, D. ; Hurault de Ligny, B. ; Kessler, M. ; Kreis, H. ; Lang, P. ; Lebranchu, Y. ; Leroux-Robert, C. ; Moulin, B. ; Mourad, G. ; Noël, C. ; Olmer, M. ; Potaux, L. ; Pouteil-Noble, C. ; Pruna, A. ; Sraër, J.D. ; Touchard, G. ; Toupance, O. ; Touraine, J.L. ; Wolf, P. ; Puget, S. ; Soulillou, J.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-6057fe3a72d94f15d901b61299a11f7bd8348c6b44caf38eb7c0546028081e993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cyclosporine - administration & dosage</topic><topic>Female</topic><topic>Graft Rejection - prevention & control</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Kidney Transplantation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hourmant, M.</creatorcontrib><creatorcontrib>Antoine, C.</creatorcontrib><creatorcontrib>Bayle, F.</creatorcontrib><creatorcontrib>Bedrossian, J.</creatorcontrib><creatorcontrib>Berthoux, F.</creatorcontrib><creatorcontrib>Cassuto, E.</creatorcontrib><creatorcontrib>Chalopin, J.M.</creatorcontrib><creatorcontrib>Charpentier, B.</creatorcontrib><creatorcontrib>Deteix, P.</creatorcontrib><creatorcontrib>Durand, D.</creatorcontrib><creatorcontrib>Hurault de Ligny, B.</creatorcontrib><creatorcontrib>Kessler, M.</creatorcontrib><creatorcontrib>Kreis, H.</creatorcontrib><creatorcontrib>Lang, P.</creatorcontrib><creatorcontrib>Lebranchu, Y.</creatorcontrib><creatorcontrib>Leroux-Robert, C.</creatorcontrib><creatorcontrib>Moulin, B.</creatorcontrib><creatorcontrib>Mourad, G.</creatorcontrib><creatorcontrib>Noël, C.</creatorcontrib><creatorcontrib>Olmer, M.</creatorcontrib><creatorcontrib>Potaux, L.</creatorcontrib><creatorcontrib>Pouteil-Noble, C.</creatorcontrib><creatorcontrib>Pruna, A.</creatorcontrib><creatorcontrib>Sraër, J.D.</creatorcontrib><creatorcontrib>Touchard, G.</creatorcontrib><creatorcontrib>Toupance, O.</creatorcontrib><creatorcontrib>Touraine, J.L.</creatorcontrib><creatorcontrib>Wolf, P.</creatorcontrib><creatorcontrib>Puget, S.</creatorcontrib><creatorcontrib>Soulillou, J.P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hourmant, M.</au><au>Antoine, C.</au><au>Bayle, F.</au><au>Bedrossian, J.</au><au>Berthoux, F.</au><au>Cassuto, E.</au><au>Chalopin, J.M.</au><au>Charpentier, B.</au><au>Deteix, P.</au><au>Durand, D.</au><au>Hurault de Ligny, B.</au><au>Kessler, M.</au><au>Kreis, H.</au><au>Lang, P.</au><au>Lebranchu, Y.</au><au>Leroux-Robert, C.</au><au>Moulin, B.</au><au>Mourad, G.</au><au>Noël, C.</au><au>Olmer, M.</au><au>Potaux, L.</au><au>Pouteil-Noble, C.</au><au>Pruna, A.</au><au>Sraër, J.D.</au><au>Touchard, G.</au><au>Toupance, O.</au><au>Touraine, J.L.</au><au>Wolf, P.</au><au>Puget, S.</au><au>Soulillou, J.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An open multicenter trial of conversion from sandimmun to neoral in stable kidney-transplant patients</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>1997-08-01</date><risdate>1997</risdate><volume>29</volume><issue>5</issue><spage>2313</spage><epage>2314</epage><pages>2313-2314</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Results obtained in organ transplantation have considerably improved with the introduction of Cyclosporine (CsA). However, the management of the drug in the sandimmun formulation is hampered by its low, highly variable bioavailability as well as the inter- and intrasubject variability of its pharmacokinetic parameters. The new galenic formulation of CsA, Neoral, based on the microemulsion principle, makes CsA absorption less dependent on gastric repletion, the presence of biliary salts and pancreatic enzymes, and concomitant administration of food. Digestive absorption and, subsequently, drug bioavailability are improved. Pharmacological studies in healthy volunteers and transplanted patients
1,2 have shown that pharmacokinetic profile of CsA becomes more reproducible from patient to patient as well as in the same patient over time.
The aim of our study was to analyze the clinical outcome and the variations in the parameters of CsA monitoring after conversion from CsA-Sandimmun (SIM) to CsA-Neoral (NEO) in stable kidney recipients transplanted for more than 6 months.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9270741</pmid><doi>10.1016/S0041-1345(97)00381-3</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1345 |
| ispartof | Transplantation proceedings, 1997-08, Vol.29 (5), p.2313-2314 |
| issn | 0041-1345 1873-2623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79235662 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Biological and medical sciences Cyclosporine - administration & dosage Female Graft Rejection - prevention & control Humans Immunomodulators Immunosuppressive Agents - administration & dosage Kidney Transplantation Male Medical sciences Middle Aged Pharmacology. Drug treatments Transplantation, Homologous Treatment Outcome |
| title | An open multicenter trial of conversion from sandimmun to neoral in stable kidney-transplant patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T14%3A23%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20open%20multicenter%20trial%20of%20conversion%20from%20sandimmun%20to%20neoral%20in%20stable%20kidney-transplant%20patients&rft.jtitle=Transplantation%20proceedings&rft.au=Hourmant,%20M.&rft.date=1997-08-01&rft.volume=29&rft.issue=5&rft.spage=2313&rft.epage=2314&rft.pages=2313-2314&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/S0041-1345(97)00381-3&rft_dat=%3Cproquest_cross%3E79235662%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79235662&rft_id=info:pmid/9270741&rft_els_id=S0041134597003813&rfr_iscdi=true |